Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences
November 16 2020 - 4:01PM
Business Wire
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell
immunotherapy, leveraging its novel allogeneic EBV T-cell platform
to develop transformative therapies for patients with serious
diseases including solid tumors, hematologic cancers and autoimmune
disease, today announced that Company management will participate
at two upcoming virtual conferences.
Stifel 2020 Virtual Healthcare Conference Wednesday,
November 18, 2020 at 4:40 p.m. EST Fireside Chat with Pascal
Touchon, President and Chief Executive Officer
Evercore ISI 3rd Annual Virtual HealthCONx Conference
Wednesday, December 2, 2020 at 8:50 a.m. EST Fireside Chat with
Pascal Touchon and Jakob Dupont, Global Head of Research and
Development
Live video webcasts of both presentations will be available by
visiting the Investor Events and Presentations section of
atarabio.com. Archived replays will be available on the Company's
website for approximately 14 days following the live webcasts.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell
immunotherapy leveraging its novel allogeneic EBV T-cell platform
to develop transformative therapies for patients with serious
diseases including solid tumors, hematologic cancers and autoimmune
disease. With our lead program in Phase 3 clinical development,
Atara is the most advanced allogeneic T-cell immunotherapy company
and intends to rapidly deliver off-the-shelf treatments to patients
with high unmet medical need. Our platform leverages the unique
biology of EBV T cells and has the capability to treat a wide range
of EBV-associated diseases, or other serious diseases through
incorporation of engineered CARs (chimeric antigen receptors) or
TCRs (T-cell receptors). Atara is applying this one platform to
create a robust pipeline including: tab-cel® (tabelecleucel) in
Phase 3 development for Epstein-Barr virus-driven post-transplant
lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell
immunotherapy targeting EBV antigens as a potential treatment for
multiple sclerosis; and multiple next-generation chimeric antigen
receptor T-cell (CAR-T) immunotherapies for both solid tumors and
hematologic malignancies. Improving patients’ lives is our mission
and we will never stop working to bring transformative therapies to
those in need. Atara is headquartered in South San Francisco and
our leading-edge research, development and manufacturing facility
is based in Thousand Oaks, California. For additional information
about the company, please visit atarabio.com and follow us on
Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201116005687/en/
Investors Eric Hyllengren Vice President, Investor
Relations & Finance Atara Biotherapeutics 805-395-9669
ehyllengren@atarabio.com
Media Kerry Beth Daly Head, Corporate Communications
Atara Biotherapeutics 516-982-9328 kdaly@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Sep 2023 to Sep 2024